Trexquant Investment’s ImmunityBio IBRX Stock Holding History

Trexquant Investment’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-36,593	Closed	-$209K	–	1186
2016 Q4	$209K	Buy	+36,593	New	+$244K	0.03%	801

Other funds holding IBRX

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Trexquant Investment's IBRX Position: Q1 2017 in Review

Trexquant Investment sold out of ImmunityBio (IBRX) in Q1 2017, closing a stake of 36,593 shares — an estimated $209K sold.

Trexquant Investment first reported a position in IBRX in Q4 2016 and held it in 1 quarter. The position peaked at $209K in Q4 2016. 60 funds tracked by Wall St. Rank hold IBRX as of Q1 2017.

Trexquant Investment reported no remaining ImmunityBio position as of Q1 2017 after selling out during the quarter.
Trexquant Investment sold 36,593 ImmunityBio shares in Q1 2017, an estimated $209K.
Trexquant Investment first reported a position in ImmunityBio in Q4 2016 and held it in 1 quarter.
Trexquant Investment's ImmunityBio position peaked at $209K in Q4 2016.
60 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2017.

Based on Trexquant Investment's 13F filing for Q1 2017, filed 9 May 2017.